Stenabolic comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-07-07. Where a claim depends on a specific study, the study is described rather than over-claimed.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
In September 2025, Eucalyptus introduced an AI chatbot prompting warning from professional bodies about the use of artificial intelligence in weight-loss programs. In late December 2025, peak eating disorder advocacy groups expressed concerns about the rapid rollout of GLP-1 weight-loss treatments alongside their aggressive marketing on social media. There were concerns from The Australia and New Zealand Academy for Eating Disorders that these marketing techniques could target people who do not need the medication. Juniper's Black Friday sale was one of the marketing practices in question.
=== Exercise fatigue === L-Ornithine supplementation has been shown to attenuate fatigue in subjects in placebo-controlled studies using a cycle ergometer. The results suggest that L-ornithine may exert an antifatigue effect by increasing the efficiency of energy consumption and promoting the excretion of ammonia.
Since the discovery and synthesis of testosterone in the 1930s, AAS have been used by physicians for many purposes, with varying degrees of success. These can broadly be grouped into anabolic, androgenic, and other uses.
They proposed the name Parmotrema chinense, based on the assumption that Osbeck's specimen corresponded to the well-known species Parmotrema perlatum. However, this proposal was not universally adopted due to the lack of valid typification and the name's absence in the literature between 1757 and 1986.
== Pharmacokinetics == Famotidine has a delayed onset of action, beginning after 90 minutes. However, famotidine has a duration of effect of at least 540 minutes (9.0 h). At its peak effect, 210 minutes (3.5 h) after administration, famotidine reduces acid secretion by 7.3 mmol per 30 minutes.
Sources: en.wikipedia.org
== Career and Discoveries == In 2000, Sen joined The Ohio State University, where he was promoted to full professor with tenure in 2004 and later awarded the John H. & Mildred C. Lumley Endowed Chair of Surgery. At Ohio State, he also served as Associate Dean of Research. Sen was the founding Executive Director of the OSU Comprehensive Wound Center and the founding Director of the OSU Center for Regenerative Medicine & Cell-Based Therapies. His research at Ohio State focused on tissue injury, repair, regeneration, and infection, including studies on stroke, tissue reprogramming, and cutaneous wound healing. This work led to the development of Tissue Nanotransfection (TNT) technology for in vivo tissue reprogramming, published in Nature Nanotechnology. TNT received a 2018 Edison Awards for Innovation. Sen's work also advanced electroceutical approaches for managing tissue infection, earning the Frost & Sullivan Award for New Product Innovation. In 2021, he was elected a Lifetime Fellow of the National Academy of Inventors. In 2018, the Indianapolis Business Journal described Sen as “one of the world's leading experts in the nascent field of regenerative medicine” when he joined Indiana University as Director of the Indiana Center for Regenerative Medicine and Engineering (ICRME), Executive Director of IU Health Comprehensive Wound Center, J. Stanley Battersby Chair and Professor of Surgery, Associate Vice President of Research, and Associate Dean for Entrepreneurial Research. He brought a team of 30 researchers and $10 million in research funding.
A significant part of the Pizza Hut brand is the red roof emblem. It was introduced as a distinctive part of the store building design in 1969, and was later incorporated into the logo. Accounts differ as to its origin; some sources state that the buildings were designed in 1963 by the Chicago architect George Lindstrom, while others state that the buildings were designed by the Wichita architect and college friend of the Carney brothers, Richard D. Burke, for the fee of $100 per store built to this design. The company's initial mascot was "Pizza Pete", a stereotypical Italian chef mascot. The Pizza Hut logo on roadside signage at this time featured the character, but this was later replaced by a graphical red roof emblem. Some people consider that the red roof emblem resembles a wide-brimmed red hat, especially in German-speaking countries, where the word Hut means hat.
Several studies point to Fyn as being responsible for dramatic biochemical changes in the oocyte cortex during oocyte maturation. Fyn may also play an important role in proper shaping of sperm head and acrosome within the testis and possibly has an additional role in the sperm acrosome reaction.
The "Source" in the project's title was later dropped when Valve asked the team to remove it in order to "stem confusion over whether or not [it was] an endorsed or official product", which at the time it was not. Eventually, the team rebranded itself as the Crowbar Collective. Most of the team was distributed across the world and used online collaboration to work remotely, with some limited in-person meetings. Originally based on the version of Source released with Counter-Strike: Source in 2004, the project switched to a more recent version released with Valve's The Orange Box in 2007. This new version included more advanced particle effects, hardware-accelerated facial animation, and support for multi-core processor rendering, amongst other improvements. The team had expected this to be a relatively fast project, with trailers released in 2005 and 2008, and an initial release estimate of late 2009, but by mid-2009, had backed off that date, and changed their expected release date to "when it's done". Wired included the game on their "Vaporware of the Year" lists in 2009 and 2010. In the lead-up to the 2012 release, team member Carlos Montero said that in 2009 that they thought they were going to be able to make that date, but "ended up busting our asses to make that a reality, and we went against a lot of our core values in the process.
Despite Cleverdon's urgings, the script slipped from Thomas's priorities and in January 1951 he went to Iran to work on a film for the Anglo-Iranian Oil Company, an assignment which Callard has speculated was undertaken on behalf of British intelligence agencies. Thomas toured the country with the film crew, and his letters home vividly express his shock and anger with the poverty he saw around him. He also gave a reading at the British Council and talked with a number of Iranian intellectuals, including Ebrahim Golestan whose account of his meeting with Thomas has been translated and published. The film was never made, with Thomas returning to Wales in February, though his time in Iran allowed him to provide a few minutes of material for a BBC documentary Persian Oil. Thomas' journey through Iran has also been the subject of the 2024 documentary film Pouring Water on Troubled Oil. The film was written and directed by Nariman Massoumi, Department of Film and Television at the University of Bristol, with narration by Michael Sheen. Later that year, Thomas published two poems, which have been described as "unusually blunt." They were an ode, in the form of a villanelle, to his dying father, Do not go gentle into that good night, and the ribald Lament. Although he had a range of wealthy patrons, including Margaret Taylor, Princess Marguerite Caetani and Marged Howard-Stepney, Thomas was still in financial difficulty, and he wrote several begging letters to notable literary figures, including T. S. Eliot.
Sources: en.wikipedia.org
Among the states and union territories of India, a union territory (UT) is a region that is directly governed by the central government of India, as opposed to the states, which have their own state government systems. Unlike states, union territories do not have their own full-fledged government but are administered by a lieutenant governor or administrator appointed by the president of India. Union territories are created for various reasons, including geographical importance, strategic necessity or historical factors. These areas are under the control of the central government to ensure uniformity in governance across the country. Some union territories, such as Delhi (National Capital Territory), Jammu and Kashmir and Puducherry have been granted special status and are allowed to have their own legislative assemblies, which can pass laws on certain matters, though the central government still retains significant authority, most importantly, the police forces and law-order. The distinction between states and union territories is defined in the Constitution of India. The Constitution designed union territories to manage areas that require more direct central control or have specific administrative needs. This ensures that regions like Ladakh and Jammu and Kashmir remain directly controlled by the central government. Currently, India has eight union territories: Andaman and Nicobar Islands, Chandigarh, Dadra and Nagar Haveli and Daman and Diu, Lakshadweep, Delhi, Puducherry, Ladakh, and Jammu and Kashmir.
=== Circulation === The octopus has three hearts, one main two-chambered heart charged with sending oxygenated blood to the body and two smaller branchial hearts, one next to each set of gills. The circulatory circuit sends oxygenated blood from the gills to the atrium of the systemic heart, then to its ventricle which pumps this blood to the rest of the body. Deoxygenated blood from the body goes to the branchial hearts which pump the blood across the gills to oxygenate it, and then the blood flows back to the systemic atrium for the process to begin again. Three aortae leave the systemic heart, two minor ones (the abdominal aorta and the gonadal aorta) and one major one, the dorsal aorta which services most of the body. The octopus also has large blood sinuses around its gut and behind its eyes that function as reserves in times of physiologic stress. The octopus' heart rate does not change significantly with exercise, though temporary cardiac arrest of the systemic heart can be induced by oxygen debt, almost any sudden stimulus, or mantle pressure during jet propulsion. Its only compensation for exertion is through an increase in stroke volume of up to three times by the systemic heart, which means it suffers an oxygen debt with almost any rapid movement. The octopus is, however, able to control how much oxygen it pulls out of the water with each breath using receptors on its gills, allowing it to keep its oxygen uptake constant over a range of oxygen pressures in the surrounding water.
== Complications == OSA is a serious medical condition with systemic effects; patients with untreated OSA have a greater mortality risk from cardiovascular disease than those undergoing appropriate treatment. The organs, which are affected the most by oxygen deprivation, are the brain and the kidneys. Other complications include hypertension, congestive heart failure, atrial fibrillation, coronary artery disease, stroke, and type 2 diabetes. Daytime fatigue and sleepiness, a common symptom of sleep apnea, is also an important public health concern regarding transportation crashes caused by drowsiness. OSA may also be a risk factor of COVID-19. People with OSA have a higher risk of developing severe complications of COVID-19. Alzheimer's disease and severe obstructive sleep apnea are connected because there is an increase in the protein beta-amyloid as well as white-matter damage. These are the main indicators of Alzheimer's, which in this case comes from the lack of proper rest or poorer sleep efficiency resulting in neurodegeneration. Having sleep apnea in mid-life brings a higher likelihood of developing Alzheimer's in older age, and if one has Alzheimer's then one is also more likely to have sleep apnea. This is demonstrated by cases of sleep apnea even being misdiagnosed as dementia. With the use of treatment through CPAP, there is a reversible risk factor in terms of the amyloid proteins. This usually restores brain structure and cognitive impairment. Evidence continues to be found supporting there is an association between BMI and Alzheimer's.
== Mechanism of action == Lubiprostone is a bicyclic fatty acid derived from prostaglandin E1 that acts by specifically activating ClC-2 chloride channels on the apical aspect of gastrointestinal epithelial cells, producing a chloride-rich fluid secretion. These secretions soften the stool, increase intestinal transit and decrease gastric emptying, and promote spontaneous bowel movements.
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.